Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Total Non-Current Liabilities (2020 - 2025)

Bioventus' Total Non-Current Liabilities history spans 6 years, with the latest figure at $439.8 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 15.31% year-over-year to $439.8 million; the TTM value through Dec 2025 reached $439.8 million, down 15.31%, while the annual FY2025 figure was $439.8 million, 15.31% down from the prior year.
  • Total Non-Current Liabilities reached $439.8 million in Q4 2025 per BVS's latest filing, down from $473.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $994.6 million in Q4 2022 to a low of $392.8 million in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $573.0 million, with a median of $557.4 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: surged 152.83% in 2022, then crashed 44.33% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $601.9 million in 2021, then skyrocketed by 56.68% to $943.0 million in 2022, then tumbled by 40.42% to $561.9 million in 2023, then fell by 7.58% to $519.2 million in 2024, then fell by 15.31% to $439.8 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Total Non-Current Liabilities are $439.8 million (Q4 2025), $473.9 million (Q3 2025), and $484.2 million (Q2 2025).